We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
MongoDB
MDB
$35.4B
| $7.56K | ﹤0.01% |
36
-9,995
| -100% | -$1.85M |
|
1852
Actinium Pharmaceuticals
ATNM
$31.4M
| $7.45K | ﹤0.01% |
5,321
-218
| -4% | -$326 |
|
|
GOGL
1853
DELISTED
Golden Ocean Group
GOGL
| $7.42K | ﹤0.01% |
1,013
-316
| -24% | -$2.4K |
|
1854
ACI Worldwide
ACIW
$5.47B
| $7.3K | ﹤0.01% |
159
-54
| -25% | -$2.65K |
|
1855
Zevra Therapeutics
ZVRA
$704M
| $7.26K | ﹤0.01% |
+824
| New | +$6.69K |
|
1856
LifeVantage
LFVN
$81.4M
| $7.19K | ﹤0.01% |
+550
| New | +$7.11K |
|
1857
Vera Bradley
VRA
$95M
| $7.16K | ﹤0.01% |
3,239
+2,759
| +575% | +$5.69K |
|
1858
Anterix
ATEX
$1.86B
| $7.11K | ﹤0.01% |
277
-58
| -17% | -$1.7K |
|
1859
VirTra
VTSI
$34.8M
| $6.85K | ﹤0.01% |
969
+567
| +141% | +$2.98K |
|
|
CSGS
1860
DELISTED
CSG Systems International
CSGS
| $6.79K | ﹤0.01% |
104
-46
| -31% | -$2.87K |
|
1861
TransUnion
TRU
$16.2B
| $6.78K | ﹤0.01% |
77
-501
| -87% | -$41.8K |
|
1862
Merit Medical Systems
MMSI
$5.35B
| $6.64K | ﹤0.01% |
71
-239
| -77% | -$22.6K |
|
1863
Chesapeake Utilities
CPK
$3.21B
| $6.61K | ﹤0.01% |
55
-58
| -51% | -$7.3K |
|
1864
Fennec Pharmaceuticals
FENC
$413M
| $6.55K | ﹤0.01% |
+789
| New | +$5.4K |
|
1865
Perdoceo Education
PRDO
$2.12B
| $6.5K | ﹤0.01% |
199
-158
| -44% | -$4.68K |
|
1866
Eagle Bancorp Montana
EBMT
$179M
| $6.5K | ﹤0.01% |
+390
| New | +$6.54K |
|
1867
Patrick Industries
PATK
$2.67B
| $6.46K | ﹤0.01% |
70
-38
| -35% | -$3.23K |
|
1868
BARK
BARK
$98M
| $6.45K | ﹤0.01% |
367
+80
| +28% | +$1.84K |
|
1869
Nkarta
NKTX
$197M
| $6.32K | ﹤0.01% |
3,805
-1,561
| -29% | -$2.86K |
|
|
HSII
1870
DELISTED
Heidrick & Struggles
HSII
| $6.32K | ﹤0.01% |
138
+81
| +142% | +$3.4K |
|
1871
Electromed
ELMD
$252M
| $6.16K | ﹤0.01% |
280
+31
| +12% | +$673 |
|
|
PRA
1872
DELISTED
ProAssurance
PRA
| $6.12K | ﹤0.01% |
268
-68
| -20% | -$1.57K |
|
1873
UBS Group
UBS
$166B
| $6.09K | ﹤0.01% |
180
| – | – |
|
1874
iShares MSCI Japan Value ETF
EWJV
$774M
| $5.94K | ﹤0.01% |
171
| – | – |
|
1875
ClearPoint Neuro
CLPT
$486M
| $5.91K | ﹤0.01% |
+495
| New | +$6.23K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.